PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Ambrx Biopharma Inc. (AMAM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS02290A1025
CUSIP02290A102
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.77B
EPS$0.42
PE Ratio66.67
Revenue (TTM)$4.09M
Gross Profit (TTM)$7.40M
EBITDA (TTM)-$61.75M
Year Range$6.55 - $28.15
Target Price$28.67
Short %3.28%
Short Ratio1.21

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with AMAM

Ambrx Biopharma Inc.

Popular comparisons: AMAM vs. VTSAX, AMAM vs. PFE, AMAM vs. KAMN, AMAM vs. SMCI, AMAM vs. PLTR

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Ambrx Biopharma Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%OctoberNovemberDecember2024FebruaryMarch
64.22%
25.63%
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Ambrx Biopharma Inc. had a return of 96.63% year-to-date (YTD) and 202.05% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date96.63%10.04%
1 month0.21%3.53%
6 months156.88%22.79%
1 year202.05%32.16%
5 years (annualized)N/A13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202495.22%0.50%
2023-7.41%-18.56%-9.48%10.85%23.40%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Ambrx Biopharma Inc. (AMAM) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
AMAM
Ambrx Biopharma Inc.
1.69
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Ambrx Biopharma Inc. Sharpe ratio is 1.69. A Sharpe ratio greater than 1.0 is considered acceptable.


Rolling 12-month Sharpe Ratio0.002.004.006.008.0010.00OctoberNovemberDecember2024FebruaryMarch
1.69
2.85
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Ambrx Biopharma Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-0.32%
-0.14%
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ambrx Biopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ambrx Biopharma Inc. was 98.18%, occurring on Dec 8, 2022. Recovery took 270 trading sessions.

The current Ambrx Biopharma Inc. drawdown is 0.32%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.18%Jul 14, 2021356Dec 8, 2022270Jan 8, 2024626
-6.45%Jun 21, 20212Jun 22, 20213Jun 25, 20215
-4.08%Jul 1, 20211Jul 1, 20212Jul 6, 20213
-2.47%Jul 9, 20212Jul 12, 20211Jul 13, 20213
-2.27%Jun 28, 20211Jun 28, 20211Jun 29, 20212

Volatility

Volatility Chart

The current Ambrx Biopharma Inc. volatility is 0.89%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%OctoberNovemberDecember2024FebruaryMarch
0.89%
2.70%
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ambrx Biopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items